MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

1 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What is EcoCharge Solutions, and Why Does it Matter Now

3 months ago

What is Google's Gemini Embedding 2 and Why Does It Matter

3 months ago

What is Upstart's Cash Line and Why Does it Matter

4 months ago

What is Pfizer's Braftovi and Why Does it Matter for Investors

4 months ago

SK pharmteco Announces SKyvec™, A Unified, High-Yield Viral Vector Platform Designed to Accelerate Gene Therapy Development from Batch to Bedside

SK pharmteco launched SKyvec, a viral vector platform integrating development and global manufacturing across North America and Europe, designed to accelerate gene therapy clinical timelines.

Stock News•1 day ago

QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy

uniQure reported early AMT-260 data showing 79-100% seizure reductions in three temporal lobe epilepsy patients, with no serious safety events.

QURE

Stock News•1 week ago

Latus Bio Appoints Bethany Mancilla as Chief Business Officer

Latus Bio appointed Bethany Mancilla as Chief Business Officer, citing her corporate development experience in gene therapy and CNS disorders. The move comes as the company advances LTS-201 toward the...

CNS

Stock News•1 week ago

Prime Medicine's Prime Editing Is Worth The Risk

Prime Medicine's PM359 data provided early human validation for Prime Editing, but management deprioritized the rare-disease program to focus on larger TAMs like Wilson Disease and AATD.

PRME